lanifibranor — Topline data
Q4 2026
Inventiva expects to report topline results from NATiV3 in the fourth quarter of 2026, as previously communicated.Source filing
IVA biotech catalysts & pipeline
INVENTIVA SA · Data as of 2026-09-08
Upcoming catalysts
lanifibranor — NDA/BLA submission
H1 2027
If the results are favorable, the Company anticipates regulatory submission in the first half of 2027 and is preparing for a potential U.S. launch of lanifibranor in 2028, subject to FDA approval.Source filing